These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1515466)

  • 1. Conjugation and evaluation of 7E3 x P4B6, a chemically cross-linked bispecific F(ab')2 antibody which inhibits platelet aggregation and localizes tissue plasminogen activator to the platelet surface.
    Neblock DS; Chang CH; Mascelli MA; Fleek M; Stumpo L; Cullen MM; Daddona PE
    Bioconjug Chem; 1992; 3(2):126-31. PubMed ID: 1515466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet monoclonal F(ab')2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart.
    Mickelson JK; Simpson PJ; Lucchesi BR
    J Mol Cell Cardiol; 1989 Apr; 21(4):393-405. PubMed ID: 2746660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiplatelet antibody [7E3 F(ab')2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model.
    Mickelson JK; Simpson PJ; Cronin M; Homeister JW; Laywell E; Kitzen J; Lucchesi BR
    Circulation; 1990 Feb; 81(2):617-27. PubMed ID: 2105175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets.
    Wagner CL; Mascelli MA; Neblock DS; Weisman HF; Coller BS; Jordan RE
    Blood; 1996 Aug; 88(3):907-14. PubMed ID: 8704248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris.
    Gold HK; Gimple LW; Yasuda T; Leinbach RC; Werner W; Holt R; Jordan R; Berger H; Collen D; Coller BS
    J Clin Invest; 1990 Aug; 86(2):651-9. PubMed ID: 2384607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic stroke.
    Zhang L; Zhang ZG; Zhang R; Morris D; Lu M; Coller BS; Chopp M
    Circulation; 2003 Jun; 107(22):2837-43. PubMed ID: 12756151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 7E3 F(ab')2, an effective antagonist of rat alphaIIbbeta3 and alphavbeta3, blocks in vivo thrombus formation and in vitro angiogenesis.
    Sassoli PM; Emmell EL; Tam SH; Trikha M; Zhou Z; Jordan RE; Nakada MT
    Thromb Haemost; 2001 May; 85(5):896-902. PubMed ID: 11372685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody.
    Yasuda T; Gold HK; Leinbach RC; Saito T; Guerrero JL; Jang IK; Holt R; Fallon JT; Collen D
    J Am Coll Cardiol; 1990 Dec; 16(7):1728-35. PubMed ID: 2123910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time course of the effects of a single bolus injection of F(ab')2 fragments of the antiplatelet GPIIb/IIIa antibody 7E3 on arterial eversion graft occlusion, platelet aggregation, and bleeding time in dogs.
    Kiss RG; Lu HR; Roskams T; Jang IK; Plow EF; Gold HK; Collen D
    Arterioscler Thromb; 1994 Mar; 14(3):367-74. PubMed ID: 8123640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of potentiation with murine antiplatelet GPIIb/IIIa antibody of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in a canine venous thrombosis model.
    Spriggs D; Gold HK; Hashimoto Y; Van Houtte E; Vermylen J; Collen D
    Thromb Haemost; 1989 Feb; 61(1):93-6. PubMed ID: 2501892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of dog platelet function by in vivo infusion of F(ab')2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor.
    Coller BS; Scudder LE
    Blood; 1985 Dec; 66(6):1456-9. PubMed ID: 2998514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation.
    Gold HK; Coller BS; Yasuda T; Saito T; Fallon JT; Guerrero JL; Leinbach RC; Ziskind AA; Collen D
    Circulation; 1988 Mar; 77(3):670-7. PubMed ID: 3124974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Identification of human platelet specific functional antibody and its fragments].
    Chu XX; Hou M; Zhu YY; Peng J; Ji XB; Zhang F; Wang L
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3464-8. PubMed ID: 16686061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. I. Adjunctive therapy with monoclonal antibody 7E3 F(ab')2 fragment.
    Rote WE; Mu DX; Bates ER; Nedelman MA; Lucchesi BR
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):194-202. PubMed ID: 7511747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibody [7E3 F(ab')2] prevents arterial but not venous rethrombosis.
    Sudo Y; Kilgore KS; Lucchesi BR
    J Cardiovasc Pharmacol; 1995 Aug; 26(2):241-50. PubMed ID: 7475049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycoprotein IIb/IIIa antagonist, murine 7E3 F(ab') 2, and tissue plasminogen activator in focal ischemia: evaluation of efficacy and risk of hemorrhage with combination therapy.
    Shuaib A; Yang Y; Nakada MT; Li Q; Yang T
    J Cereb Blood Flow Metab; 2002 Feb; 22(2):215-22. PubMed ID: 11823719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet-targeted fibrinolysis enhances clot lysis and inhibits platelet aggregation.
    Bode C; Meinhardt G; Runge MS; Freitag M; Nordt T; Arens M; Newell JB; Kübler W; Haber E
    Circulation; 1991 Aug; 84(2):805-13. PubMed ID: 1860223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibody Fab' fragment cross-linking using equilibrium transfer alkylation reagents. A strategy for site-specific conjugation of diagnostic and therapeutic agents with F(ab')2 fragments.
    Wilbur DS; Stray JE; Hamlin DK; Curtis DK; Vessella RL
    Bioconjug Chem; 1994; 5(3):220-35. PubMed ID: 7918742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inhibition of thrombocyte aggregation by F(ab')2-fragments of monoclonal antibodies FraMon (CRC64) to glycoproteins IIb-IIIa].
    Mazurov AV; Pevzner DV; Khaspekova SG; Dudnik OA; Byzova TV; Vlasik TN; Bakharev VN; Pistsov MIu; Staroverov II; Ruda MIa
    Ter Arkh; 2001; 73(9):66-73. PubMed ID: 11642086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flow cytometric observations on the in vivo use of Fab fragments of a chimaeric monoclonal antibody to platelet glycoprotein IIb-IIIa.
    Christopoulos C; Mackie I; Lahiri A; Machin S
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):729-37. PubMed ID: 8292722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.